$MRK Company News Correction: Blog points out
Post# of 94122
![Avatar](/images/ProfileImages/410421673_9050_Stock_Tracker.jpg)
Correction: Blog points out Valeant's diverse portfolio is key to its success 1:53 p.m. July 21, 2014 - blogs.marketwatch.com
How to buy momentum stocks without getting burned 9:22 a.m. July 7, 2014 - Jonathan Burton
Nike, Pfizer, Merck among Dow top gainers 4:02 p.m. June 25, 2014 - William L. Watts
How investors can tap into multibillion-dollar premiums 12:15 p.m. June 17, 2014 - David Weidner
Newscast: Stocks ease back from records 12:45 p.m. June 10, 2014 - MarketWatch
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stocks close up; S&P 500, Dow at record 4:42 p.m. June 9, 2014 - Anora Mahmudova
Newscast: Wall Street extends its record run 4:28 p.m. June 9, 2014 - MarketWatch
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Merger Monday deals come with high premiums 12:30 p.m. June 9, 2014 - blogs.marketwatch.com
Newscast: Merger news lifts stocks 12:23 p.m. June 9, 2014 - MarketWatch
Short-sellers are all over this market, and that's good news for bulls 9:51 a.m. June 9, 2014 - blogs.marketwatch.com
Merck to buy Idenix for $3.85 billion 9:23 a.m. June 9, 2014 - Erin McCarthy
Stock futures off; Family Dollar, Tyson, are active 8:52 a.m. June 9, 2014 - Barbara Kollmeyer
Merck to buy Idenix for $24.50 per share 7:53 a.m. June 9, 2014 - Ben Eisen
Idenix acquisition delivers Merck hepatitis C portfolio 7:38 a.m. June 9, 2014 - Ben Eisen
Merck buyout values Idenix at $3.85 billion 7:36 a.m. June 9, 2014 - Ben Eisen
Merck to buy Idenix for $24.50 per share 7:35 a.m. June 9, 2014 - Ben Eisen
Merck, Sanofi, Glaxo explore shedding older drugs 5:42 p.m. June 3, 2014 - MarketWatch.com
TripAdvisor leads momentum-play rally to lift Nasdaq 3:52 p.m. May 12, 2014 - Saumya Vaishampayan
9 Health Care Stocks From Index-Crushing Fund 7:45 p.m. July 25, 2014 - Barrons.com
Week Ahead: July Jobs Report, FOMC and GDP 4:46 p.m. July 25, 2014 - FOXBusiness
Merck continues cutting jobs 11:22 a.m. July 25, 2014 - Seeking Alpha
Key Short Interest Changes in Defensive High-Yield Dividend Stocks 9:58 a.m. July 25, 2014 - 247WallSt.com
Merck Layoffs: MRK to Cut Another 600 Jobs 9:26 a.m. July 25, 2014 - InvestorPlace.com
Alnylam And Benitec 8:16 a.m. July 25, 2014 - Seeking Alpha
Cramer's Mad Money - 2 Picks From Leon Cooperman (7/24/14) 6:08 a.m. July 25, 2014 - Seeking Alpha
Merck Looks Overpriced Compared To This Sector Peer 5:42 p.m. July 24, 2014 - Seeking Alpha
Can GlaxoSmithKline’s Slumping Stock Recover? 4:40 p.m. July 24, 2014 - Wall St. Cheat Sheet
Hepatitis C Pill Rockets Gilead Into Big Leagues 2:18 p.m. July 24, 2014 - The Wall Street Journal Interactive Edition
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds 1:48 p.m. July 24, 2014 - Zacks.com
How Doctor Got Rich Invoking Antifraud Law 11:39 a.m. July 24, 2014 - The Wall Street Journal Interactive Edition
Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year 11:25 a.m. July 24, 2014 - Seeking Alpha
Beneath the Surface, Dow Doesn't Look So Healthy 8:22 a.m. July 24, 2014 - Barrons.com
Is Inovio Undervalued After Positive HPV Therapy Results? 4:19 p.m. July 23, 2014 - Seeking Alpha
Stock Market News for July 23, 2014 - Market News 10:10 a.m. July 23, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: MDLZ, MRK, IBM 4:14 p.m. July 22, 2014 - TheStreet.com
Bad Times Continue To Hit Merck's Animal Health Segment 5:52 a.m. July 22, 2014 - Seeking Alpha
ABBV, MRK And PFE, Pushing Health Care Sector Downward 1:03 p.m. July 21, 2014 - TheStreet.com
5 More Possible Partners For MannKind's Afrezza, Each With A Strong Diabetes Care Franchise 9:53 a.m. July 21, 2014 - Seeking Alpha
Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients 8:30 a.m. July 24, 2014 - BusinessWire - BZX
Insomnia Global Clinical Trials Review, H2, 2014 1:14 p.m. July 23, 2014 - PR Newswire - PRF
Merck Announces Fourth-Quarter 2014 Dividend 12:15 p.m. July 23, 2014 - BusinessWire - BZX
Financial Results, Campaign Launch, and New Steps in Facility Planning - Research Reports on Johnson & Johnson, Merck, AstraZeneca, Novartis and Teva 8:00 a.m. July 23, 2014 - PR Newswire - PRF
Viamet Announces Appointment of Amir Tavakkol, Ph.D., as Chief Development Officer 10:01 a.m. July 22, 2014 - BusinessWire - BZX
Milestone Pharmaceuticals Appoints Chief Medical Officer 9:00 a.m. July 21, 2014 - PR Newswire - PRF
Technical Pointers on Pharma Equities -- AbbVie, Johnson and Johnson, Merck, Bristol-Myers Squibb, and Eli Lilly 8:40 a.m. July 21, 2014 - PR Newswire - PRF
Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment 8:30 a.m. July 17, 2014 - PR Newswire - PRF
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 4:55 p.m. July 15, 2014 - PR Newswire - PRF
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool 4:11 p.m. July 15, 2014 - PR Newswire - PRF
Type 2 Diabetes Global Clinical Trials Review, H1, 2014 3:31 p.m. July 15, 2014 - PR Newswire - PRF
Medivation Announces Change in Executive Management Team 4:10 p.m. July 10, 2014 - Marketwire
Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 Market 12:38 p.m. July 10, 2014 - PR Newswire - PRF
Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 10:00 a.m. July 10, 2014 - PR Newswire - PRF
Baxter Appoints John Orloff, M.D., Vice President of BioScience R&D 9:00 a.m. July 10, 2014 - BusinessWire - BZX
Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer 7:00 a.m. July 10, 2014 - BusinessWire - BZX
New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo 5:00 a.m. July 10, 2014 - PR Newswire - PRF
BeiGene Enrolls First Patient in Phase 1 Study of BGB-290 9:06 a.m. July 7, 2014 - BusinessWire - BZX
Oxford Immunotec Appoints Louis O'Dea Chief Medical Officer 7:01 a.m. July 7, 2014 - GlobeNewswire
Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck 2:33 a.m. July 2, 2014 - GlobeNewswire
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)